EUCTR2005-002437-13-IT进行中（未招募）不适用
Early access of TMC114 in combination with low-dose ritonavir RTV and other antiretrovirals ARVs in highly treatment experienced HIV-1 infected subjects with limited to no treatment options. - TMC114-C226
TIBOTEC PHARMACEUTICALS LTD.0 个研究点目标入组 15,000 人开始时间: 2006年4月21日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 15,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Early access of TMC114 in combination with low-dose ritonavir (RTV) and other antiretrovirals (ARVs) in highly treatment experienced HIV-1 infected subjects with limited to no treatment options.EUCTR2005-002437-13-LTTibotec Pharmaceuticals Ltd.5,000
已完成
4 期
Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Treatment Experienced in HIV-1 PatientsHIV-1NCT01702090Janssen-Cilag Ltd.10
Approved For Marketing
不适用
TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.HIV InfectionsNCT00245739Tibotec Pharmaceuticals, Ireland
进行中（未招募）
不适用
未命名试验EUCTR2006-002499-16-DEJanssen R&D Ireland
已完成
不适用
Early Access of TMC125 in combination with other antiretrovirals in treatment-experienced HIV-1 infected subjects with limited treatment options.HIV-110047438NL-OMON30522Janssen-Cilag120